SCOTTSDALE, AZ --
Dunkin' Donuts readies for National Cookie Day with special Twitter sweepstakes to celebrate holiday and brand's cookie-flavored coffee and lattes For Cyber Monday, Dunkin' Donuts Packaged Coffee deal and Dunkin' Donuts Cards can keep friends, family and co-workers running on Dunkin' throughout the holidays and into 2015
Kinder Morgan, Inc. (NYSE: KMI) today announced it has completed its
acquisition of the outstanding equity securities of Kinder Morgan Energy
Partners, L.P. (NYSE: KMP), Kinder Morgan Management, LLC (NYSE: KMR)
and El Paso Pipeline Partners, L.P. (NYSE: EPB). The approximately $76
billion transaction was initially announced Aug.
Sign-up for WILLBROS GROUP SHAREHOLDER ALERT: National Securities Law Firm Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Willbros Group, Inc. to Contact Law Firm investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that a pre-specified analysis of investigational data
from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA®
(pembrolizumab), the company’s anti-PD-1 therapy, substantially improved
the primary endpoint of progression-free survival (PFS, as assessed by
RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg
and 10 mg/kg every three week doses, respectively), compared to
chemotherapy (P<0.0001 for both comparisons) in patients with
ipilimumab-refractory advanced melanoma (n=540). At six months, the PFS
rates for KEYTRUDA were 34 percent at the 2 mg/kg dose (95% CI, 27-41)
(n=180) and 38 percent at the 10 mg/kg dose (95% CI, 31-45) (n=181),
compared to 16 percent for chemotherapy (95% CI, 10-22) (n=179). The
median duration of follow-up at the interim analysis was 10 months.
Binkow & Goldberg LLP announces that a class action lawsuit has
been filed in the United States District Court for the Western District
of Oklahoma on behalf of a class (the “Class”) comprising all persons or
entities who purchased the securities of SandRidge
Energy, Inc. (“SandRidge” or the “Company”) (NYSE:SD) between March
1, 2013 and November 4, 2014, inclusive (the “Class Period”).
Please contact Lesley
Portnoy or Casey
Sadler at (888) 773-9224 or (310) 201-9150, or at email@example.com
to discuss this matter.
Squibb Company (NYSE:BMY) today announced positive results from
CheckMate -037, a Phase 3 randomized, controlled open-label study of Opdivo
(nivolumab), an investigational PD-1 immune checkpoint inhibitor,
versus investigator’s choice chemotherapy (ICC) in patients with
advanced melanoma who were previously treated with Yervoy
(ipilimumab). Based on a planned interim analysis of the co-primary
endpoint, the objective response rate (ORR) was 32% (95% CI = 24, 41) in
the Opdivo arm (n=120) and 11% (95% CI = 4, 23) in the ICC
reference arm (n=47) in patients with at least six months of follow up.
Sign-up for Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor investment picks
Old Navy's Second Annual "Overnight Millionaire" Giveaway Offers Best Odds Ever to Win $1 Million this Black Friday #onemillthrill Canada NewsWire
Entire Store 50% Off on Black Friday 1,000 shoppers treated to a $200 shopping spree over Black Friday weekend TORONTO , Nov.
2015 Travato Class B motorhome from Winnebago
Grand Tour 42HL
FOREST CITY, IA--(Marketwired - October 10, 2014) - Winnebago Industries, Inc. (NYSE: WGO), a leading United States (U.S.) recreation vehicle manufacturer, has a host of new 2015 products on display at the RVIA's Annual California RV Show taking place October 10-19, 2014 at the Fairplex in Pomona.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.